Clinical sequencing of the retinitis pigmentosa gene RPGR in over 1,000 cases of vision loss
Molecular Vision · 2024
DOI: 10.63500/mv_v30_49 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Vision, 2024. Verfasst von Madhulatha Pantrangi und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
RPGR pathogenic variants are the major cause of X-linked retinitis pigmentosa. Here, we report the results from 1,033 clinical DNA tests that included sequencing of RPGR. A total of 184 RPGR variants were identified: 78 pathogenic or likely pathogenic, 14 uncertain, and 92 likely benign or benign. Among the pathogenic and likely pathogenic variants, 23 were novel, and most were frameshift or nonsense mutations (87%) and enriched (67%) in RPGR exon 15 (ORF15). Identical pathogenic variants found in different families were largely on different haplotype backgrounds, indicating relatively frequent, recurrent RPGR mutations. None of the 16 mother/affected son pairs showed de novo mutations; all 16 mothers were heterozygous for the pathogenic variant. These last two observations support the occurrence of most RPGR mutations in the male germline.
Zitieren
APA
Pantrangi, M., Rath, J., Kaetterhenry, N., Branham, K., Talsness, D., & Weber, J. L. (2024). Clinical sequencing of the retinitis pigmentosa gene RPGR in over 1,000 cases of vision loss. Molecular Vision. https://doi.org/10.63500/mv_v30_49
Vancouver
Pantrangi M, Rath J, Kaetterhenry N, Branham K, Talsness D, Weber JL. Clinical sequencing of the retinitis pigmentosa gene RPGR in over 1,000 cases of vision loss. Molecular Vision. 2024. doi:10.63500/mv_v30_49
BibTeX
@article{Pantrangi2024,
author = {Pantrangi, Madhulatha and Rath, Julie and Kaetterhenry, Nicole and Branham, Kari and Talsness, Dana and Weber, James L.},
title = {Clinical sequencing of the retinitis pigmentosa gene RPGR in over 1,000 cases of vision loss},
journal = {Molecular Vision},
year = {2024},
doi = {10.63500/mv_v30_49}
}
EUVIMED